Sun Pharma Advanced Research Co (BOM:532872) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sun Pharma Advanced Research Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Sun Pharma Advanced Research Co ROCE % Historical Data

The historical data trend for Sun Pharma Advanced Research Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharma Advanced Research Co ROCE % Chart

Sun Pharma Advanced Research Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-181.85

-837.59

-362.06

-56.58

-85.59

Sun Pharma Advanced Research Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-75.77	-87.40	-168.01	-151.91	-

Sun Pharma Advanced Research Co ROCE % Calculation

Sun Pharma Advanced Research Co's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	-3856.373	/	( ( (8301.261 - 1789.457)	+	(5150.422 - 2650.578) )	/ 2 )
	=	-3856.373	/	( (6511.804	+	2499.844)	/ 2 )
	=	-3856.373	/	4505.824
	=	-85.59 %

Sun Pharma Advanced Research Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-4241.2	/	( ( (0 - 0)	+	(0 - 0) )	/ 1 )
	=	-4241.2	/	( ( 0	+	0 )	/ 1 )
	=	-4241.2	/	0
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Sun Pharma Advanced Research Co (BOM:532872) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sun Pharma Advanced Research Co ROCE % Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Pharma Advanced Research Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (BOM:532872) » Definitions » ROCE %

Traded in Other Exchanges

SPARC:India

Address

Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093

Website

https://www.sparc.life

Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in othe4r countries.

Sun Pharma Advanced Research Co Headlines

No Headlines